KALYDECO

Reason for request

Clinical Benefit

Substantial

Substantial actual benefit

Clinical Added Value

important

KALYDECO offers a substantial improvement in actual benefit (IAB II) in the treatment of cystic fibrosis in patients aged 6 years and older with the G551D-CFTR mutation.